Fig. 3 | Scientific Reports

Fig. 3

From: Pretreatment neutrophil–lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumab

Fig. 3

Kaplan–Meier survival curves for OS and PFS according to the CAR. (A, B) Kaplan–Meier Curves for All Regimens: OS (A) and PFS (B). (C, D) Kaplan–Meier Curves for Pembrolizumab Plus Chemotherapy: OS (C) and PFS (D). (E, F) Kaplan–Meier Curves for Pembrolizumab Monotherapy: OS (E) and PFS (F). OS: overall survival; PFS: progression-free survival; CAR: C-reactive protein-to-albumin ratio.

Back to article page